Archive Adhoc- and Press releases 2016

ENGLISH DEUTSCH
26 October 2016
PR: WILEX AG: Subsidiary Heidelberg Pharma and Nordic Nanovector Enter into Collaboration to Develop Novel Antibody Drug Conjugates (ADC)
13 October 2016
PR: WILEX AG: Interim Management Statement on the First Nine Months of 2016
11 October 2016
AH: WILEX AG secures further financing with shareholder loan based on an existing financing commitment
27 September 2016
PR: WILEX AG: Subsidiary Heidelberg Pharma contracts Suisse CDMO Celonic for antibody cell line development and antibody production
19 September 2016
PR: WILEX AG: Subsidiary Heidelberg Pharma Signs Option Agreement with Max Delbrück Center
14 July 2016
PR: WILEX publishes Half-yearly Financial Report
28 June 2016
PR: WILEX AG: European Patent Office grants patent for the chemical synthetic building block dihydroxyisoleucine for the production of Amanitin
14 June 2016
PM: Advanced Proteome Therapeutics Corporation and WILEX subsidiary Heidelberg Pahrma collaborate to create improve cancer therapeutics
2 June 2016
PR: WILEX AG announces change on the Executive Management Board
AH: WILEX AG announces change on the Executive Management Board
25 April 2016
PR: WILEX AG successfully completes capital increase
14 April 2016
PR: WILEX AG: Interim management statement on the first quarter of 2016
6 April 2016
PR: WILEX AG plans change on Supervisory Board
4 April 2016
AH: WILEX AG plans rights issue using authorised capital
22 March 2016
PR: WILEX announces financial figures for the 2015 financial year and reports on course of business
2 February 2016
PR: WILEX AG: US-patent office granted patent for amatoxin conjugates for tumour therapy
13 January 2016
PR: WILEX’s partner Link Health submits IND application for clinical Phase I with the uPA inhibitor MESUPRON® in China

 

Seite gelesen: 229 | Heute: 2